+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

H1N1 Vaccines: Global Strategic Business Report

  • PDF Icon

    Report

  • 268 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227784

Global H1N1 Vaccines Market to Reach $3.2 Billion by 2030

The global market for H1N1 Vaccines estimated at US$2.2 Billion in the year 2022, is projected to reach a revised size of US$3.2 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2022-2030. Intramuscular, one of the segments analyzed in the report, is projected to record 6.2% CAGR and reach US$1.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Intranasal segment is readjusted to a revised 5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $588.1 Million, While China is Forecast to Grow at 8.7% CAGR

The H1N1 Vaccines market in the U.S. is estimated at US$588.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$734.5 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Select Competitors (Total 33 Featured) -

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for H1N1 Vaccines

What is the estimated value of the Global Market for H1N1 Vaccines?

The Global Market for H1N1 Vaccines was estimated to be valued at $1.9 Billion in 2020.

What is the growth rate of the Global Market for H1N1 Vaccines?

The growth rate of the Global Market for H1N1 Vaccines is 5.1%, with an estimated value of $2.7 Billion by 2027.

What is the forecasted size of the Global Market for H1N1 Vaccines?

The Global Market for H1N1 Vaccines is estimated to be worth $2.7 Billion by 2027.

Who are the key companies in the Global Market for H1N1 Vaccines?

Key companies in the Global Market for H1N1 Vaccines include Abbott Laboratories, Inc., Baxter International, Inc., Cipla Ltd., GlaxoSmithKline PLC, Hualan Biological Engineering, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer, Inc., Sanofi and Sinovac Biotech Ltd..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • H1N1 Vaccines - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 2: World 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2023 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 4: World 8-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 6: World 8-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 8: World 8-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 10: World 8-Year Perspective for Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 12: World 8-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 14: World 8-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
  • Table 15: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 16: World 8-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
  • Table 17: World H1N1 Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 18: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 19: USA 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
CANADA
  • Table 20: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 21: Canada 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
JAPAN
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 22: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 23: Japan 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
CHINA
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 24: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 25: China 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
EUROPE
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 26: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 27: Europe 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2023 & 2030
  • Table 28: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 29: Europe 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
FRANCE
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 30: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 31: France 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
GERMANY
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 32: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: Germany 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
ITALY
  • Table 34: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 35: Italy 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
UNITED KINGDOM
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 36: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 37: UK 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
SPAIN
  • Table 38: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: Spain 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
RUSSIA
  • Table 40: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 41: Russia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
REST OF EUROPE
  • Table 42: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 43: Rest of Europe 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
ASIA-PACIFIC
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 44: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 45: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2023 & 2030
  • Table 46: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 47: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
AUSTRALIA
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • Table 48: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 49: Australia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
INDIA
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • Table 50: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: India 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
SOUTH KOREA
  • Table 52: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 53: South Korea 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
REST OF ASIA-PACIFIC
  • Table 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 55: Rest of Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
LATIN AMERICA
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • Table 56: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 57: Latin America 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2023 & 2030
  • Table 58: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 59: Latin America 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
ARGENTINA
  • Table 60: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 61: Argentina 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
BRAZIL
  • Table 62: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 63: Brazil 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
MEXICO
  • Table 64: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 65: Mexico 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
REST OF LATIN AMERICA
  • Table 66: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 67: Rest of Latin America 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
MIDDLE EAST
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • Table 68: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 69: Middle East 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2023 & 2030
  • Table 70: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 71: Middle East 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
IRAN
  • Table 72: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 73: Iran 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
ISRAEL
  • Table 74: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 75: Israel 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
SAUDI ARABIA
  • Table 76: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 77: Saudi Arabia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
UNITED ARAB EMIRATES
  • Table 78: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 79: UAE 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
REST OF MIDDLE EAST
  • Table 80: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 81: Rest of Middle East 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
AFRICA
  • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
  • Table 82: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 83: Africa 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.